Alexandra Clement

Dr. Alexandra Clement

Cardiology Department, Cardiovascular Diseases Institute "Prof Dr. I.M.Georgescu" Iasi, Romania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
RSRadu Andy Sascau
Radu Andy Sascau
ACAlexandra Clement
Alexandra Clement
RRRodica Radu
Rodica Radu
CPCristina Prisacariu
Cristina Prisacariu
CRISTIAN STATESCUCRISTIAN STATESCU
CRISTIAN STATESCU
While targeting elevated serum levels of low-density lipoprotein cholesterol has been the mainstay of atherosclerosis prevention and treatment for decades, the evidence regarding the atherogenic role of hypertriglyceridemia is still controversial. Various epidemiological population-based studies on statin-treated subjects nominated triglycerides, triglyceride-rich lipoproteins (namely, chylomicrons and very-low-density lipoprotein particles), and their remnants as major determinants of the substantial residual cardiovascular risk. With the triglyceride-glucose index and triglyceride to high-density lipoprotein ratio emerging as surrogate indicators of peripheral artery disease and atherosclerotic cerebrovascular disease, one can conclude that further research addressing the intricate relationship between triglycerides and atherosclerosis is warranted. Therefore, this review aims to provide insight into the current clinical and epidemiological state of knowledge on the relationship between triglycerides and atherosclerotic cardiovascular disease. It also intends to highlight the connection between triglycerides and other metabolic disorders, including diabetes mellitus, and the potential benefits of triglyceride-lowering agents on cardiovascular outcomes and all-cause mortality.

25 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
CRISTIAN STATESCUCRISTIAN STATESCU
CRISTIAN STATESCU
ACAlexandra Clement
Alexandra Clement
Ionela Lacramioara SerbanIonela Lacramioara Serban
Ionela Lacramioara Serban
RSRadu Andy Sascau
Radu Andy Sascau
In the past few decades, research has focused on the importance of addressing modifiable risk factors as a means of lowering the risk of cardiovascular disease (CVD), which represents the worldwide leading cause of death. For quite a long time, it has been considered that ethanol intake has a biphasic impact on the cardiovascular system, mainly depending on the drinking pattern, amount of consumption, and type of alcoholic beverage. Multiple case-control studies and meta-analyses reported the existence of a “U-type” or “J-shaped” relationship between alcohol and CVD, as well as mortality, indicating that low to moderate alcohol consumption decreases the number of adverse cardiovascular events and deaths compared to abstinence, while excessive alcohol use has unquestionably deleterious effects on the circulatory system. However, beginning in the early 2000s, the cardioprotective effects of low doses of alcohol were abnegated by the results of large epidemiological studies. Therefore, this narrative review aims to reiterate the association of alcohol use with cardiac arrhythmias, dilated cardiomyopathy, arterial hypertension, atherosclerotic vascular disease, and type 2 diabetes mellitus, highlighting literature disagreements over the risk and benefits of low to moderate drinking on the cardiovascular system.

Verified
Journal Article
Open access
PDF file
TCTraian Chiuariu
Traian Chiuariu
DSDelia Lidia Salaru
Delia Lidia Salaru
Carina UrecheCarina Ureche
Carina Ureche
LVLaura Vasiliu
Laura Vasiliu
ALAncuta Lupu
Ancuta Lupu
CRISTIAN STATESCUCRISTIAN STATESCU
CRISTIAN STATESCU
Cardiovascular disease (CVD) and chronic kidney disease (CKD) often coexist and have a major impact on patient prognosis. Organ fibrosis plays a significant role in the pathogenesis of cardio-renal syndrome (CRS), explaining the high incidence of heart failure and sudden cardiac death in these patients. Various mediators and mechanisms have been proposed as contributors to the alteration of fibroblasts and collagen turnover, varying from hemodynamic changes to the activation of the renin–angiotensin system, involvement of FGF 23, and Klotho protein or collagen deposition. A better understanding of all the mechanisms involved has prompted the search for alternative therapeutic targets, such as novel inhibitors of the renin–angiotensin–aldosterone system (RAAS), serelaxin, and neutralizing interleukin-11 (IL-11) antibodies. This review focuses on the molecular mechanisms of cardiac and renal fibrosis in the CKD and heart failure (HF) population and highlights the therapeutic alternatives designed to target the responsible pathways.

28 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Larisa AnghelLarisa Anghel
Larisa Anghel
Bogdan-Sorin TudurachiBogdan-Sorin Tudurachi
Bogdan-Sorin Tudurachi
ATAndreea Tudurachi
Andreea Tudurachi
AZAlexandra Zăvoi
Alexandra Zăvoi
ACAlexandra Clement
Alexandra Clement
CRISTIAN STATESCUCRISTIAN STATESCU
CRISTIAN STATESCU
Over the past four decades, percutaneous coronary intervention (PCI) safety and efficacy have significantly improved, particularly with the advent of the drug-eluting stent (DES). First-generation DESs reduced in-stent restenosis rates and targeted lesion revascularization; however, safety issues emerged, due to high incidences of stent thrombosis (ST) linked to death, myocardial infarction, and repeat revascularization. Second-generation DESs were developed to overcome these issues, reducing late-thrombotic-event risk while maintaining anti-restenosis efficacy. Nevertheless, ST still occurs with second-generation DES use. Stent thrombosis etiology is multifaceted, encompassing lesion-, patient-, procedural-, and stent-related factors. Overall, most early-stent-thrombosis cases are linked to procedural and patient-related aspects. Factors like premature discontinuation of dual antiplatelet therapy, resistance to clopidogrel, smoking, diabetes mellitus, malignancy, reduced ejection fraction or undertaking coronary angioplasty for an acute coronary syndrome can increase the risk of stent thrombosis. The aim of this study is to assess patient-related factors that potentially heighten the risk of stent thrombosis, with the objective of pinpointing and addressing modifiable contributors to this risk. By focusing on both patient- and procedure-related factors, a multifaceted approach to coronary revascularization can help minimize complications and maximize long-term benefits in managing ST.

7 February 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
RSRadu Andy Sascau
Radu Andy Sascau
Larisa AnghelLarisa Anghel
Larisa Anghel
ACAlexandra Clement
Alexandra Clement
MBMadalina Bostan
Madalina Bostan
RRRodica Radu
Rodica Radu
CRISTIAN STATESCUCRISTIAN STATESCU
CRISTIAN STATESCU
Infiltrative cardiomyopathies (ICMs) comprise a broad spectrum of inherited and acquired conditions (mainly amyloidosis, sarcoidosis, and hemochromatosis), where the progressive buildup of abnormal substances within the myocardium results in left ventricular hypertrophy and manifests as restrictive physiology. Noninvasive multimodality imaging has gradually eliminated endomyocardial biopsy from the diagnostic workup of infiltrative cardiac deposition diseases. However, even with modern imaging techniques’ widespread availability, these pathologies persist in being largely under- or misdiagnosed. Considering the advent of novel, revolutionary pharmacotherapies for cardiac amyloidosis, the archetypal example of ICM, a standardized diagnostic approach is warranted. Therefore, this review aims to emphasize the importance of contemporary cardiac imaging in identifying specific ICM and improving outcomes via the prompt initiation of a targeted treatment.

28 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
TITeodor Marian Ionescu
Teodor Marian Ionescu
Manuela CiocoiuManuela Ciocoiu
Manuela Ciocoiu
RLRaoul-Vasile Lupuşoru
Raoul-Vasile Lupuşoru
IGIrena Cristina Grierosu
Irena Cristina Grierosu
RSRadu Andy Sascau
Radu Andy Sascau
CSCipriana Stefanescu
Cipriana Stefanescu
Transthyretin cardiac amyloidosis (ATTR) is a rare cardiac protein deposition disease characterized by progressive thickening of both ventricles, the inter-atrial-ventricular septum and the atrioventricular valves. The gold standard method for diagnosing this rare pathology is endomyocardial biopsy. If this method cannot be used, the alternative is a mixture of clinical and paraclinical tests. Over the course of five years, we examined 58 patients suspected of cardiac amyloidosis based on electrocardiography and ultrasonography criteria, who had been sent for bone scintigraphy in order to determine the presence of ATTR cardiac amyloidosis. However, the final diagnosis was set by correlating the bone scan with genetic testing, free light chain dosage or soft tissue biopsy. Based on the final diagnosis we analyzed the patients’ predominant biomarkers in order to determine a possible correlation between them. This analysis is designed to help the general practitioner set a possible cardiac amyloidosis diagnosis.